Core Viewpoint - Marker Therapeutics, Inc. is set to present its technology and clinical developments at the Citizens JMP Hematology and Oncology Summit on December 2, 2024, highlighting its focus on next-generation T cell-based immunotherapies for hematological malignancies and solid tumors [1][2]. Company Overview - Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company based in Houston, TX, specializing in developing T cell-based immunotherapies for treating hematological malignancies and solid tumors [5]. - The company has conducted clinical trials involving over 200 patients, demonstrating that its autologous and allogeneic multiTAA-specific T cell products are well tolerated and show durable clinical responses [5]. - Marker aims to introduce novel T cell therapies to the market to improve patient outcomes while prioritizing financial resource preservation and operational excellence [5]. - The company benefits from non-dilutive funding from U.S. state and federal agencies that support cancer research, strengthening its unique T cell platform [5]. Event Details - Dr. Juan Vera, President and CEO of Marker Therapeutics, will present at the Citizens JMP Hematology and Oncology Summit on December 2, 2024, at 11 AM EST [2][3]. - The event will be held virtually, and a replay of Dr. Vera's presentation will be available on the company's Investor Relations website [3]. - During the conference, Dr. Vera and the Marker management team will conduct one-on-one meetings with registered investors to showcase the company's business and clinical development [4].
Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit